Permira Is Said to Weigh €3 Billion-Plus Sale of Neuraxpharm

Permira is considering a sale of Neuraxpharm in a deal that could value the pharmaceutical company that focuses on central nervous system disorders at €3 billion ($3.5 billion) to €4 billion, according to people familiar with the matter.

The private equity firm is talking to potential advisers and the sale process could start as soon as later this year, the people said, asking not to be identified as the information is private.